Aspectos celulares y moleculares de la nefropatía diabética, rol del VEGF-A

Guariguata, 2014, Global estimates of diabetes prevalence for 2013 and projections for 2035, Diabetes Res Clin Pract., 103, 137, 10.1016/j.diabres.2013.11.002 Aschner, 2013, en representación del IDF Diabetes Atlas. Diabetes in South and Central America: An update for 2013 for the IDF Diabetes Atlas, Diabetes Res Clin Pract., 103, 238, 10.1016/j.diabres.2013.11.010 Soriguer, 2012, Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the [email protected] Study, Diabetologia., 55, 88, 10.1007/s00125-011-2336-9 Escobedo, 2009, CARMELA Study Investigators. High prevalence of diabetes and impaired fasting glucose in urban Latin America: the CARMELA Study, Diabet Med., 26, 864, 10.1111/j.1464-5491.2009.02795.x Castillo-Tandazo, 2013, Spanish translation, cross-cultural adaptation, and validation of the Questionnaire for Diabetes-Related Foot Disease (Q-DFD), Vasc Health Risk Manag., 9, 501, 10.2147/VHRM.S49749 Neira-Mosquera, 2013, Study on the mortality in Ecuador related to dietary factors, Nutr Hosp., 28, 1732 Gonzalez Suarez, 2013, Diabetic nephropathy: Is it time yet for routine kidney biopsy?, World J Diabetes., 4, 245, 10.4239/wjd.v4.i6.245 Tuttle, 2014, Diabetic kidney disease: A report from an ADA Consensus Conference, Diabetes Care., 37, 2864, 10.2337/dc14-1296 Eggers, 2011, Has the incidence of end-stage renal disease in the USA and other countries stabilized?, Curr Opin Nephrol Hypertens., 20, 241, 10.1097/MNH.0b013e3283454319 Lugon, 2010, Disparities in end-stage renal disease care in South America, Clin Nephrol., 74, S66 Rosa-Diez, 2014, Renal replacement therapy in Latin American end-stage renal disease, Clin Kidney J., 7, 431, 10.1093/ckj/sfu039 Fried, 2013, Combined angiotensin inhibition for the treatment of diabetic nephropathy, N Engl J Med., 14, 1892, 10.1056/NEJMoa1303154 Roscioni, 2014, The effect of RAAS blockade on the progression of diabetic nephropathy, Nat Rev Nephrol., 10, 77, 10.1038/nrneph.2013.251 Adler, 2003, UKPDS Group. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64), Kidney Int, 63, 225, 10.1046/j.1523-1755.2003.00712.x Tufro, 2012, VEGF podocytes in diabetic nephropathy, Semin Nephrol., 32, 385, 10.1016/j.semnephrol.2012.06.010 Mooyaart, 2011, Genetic associations in diabetic nephropathy: a meta-analysis, Diabetologia., 54, 544, 10.1007/s00125-010-1996-1 Sapienza, 2011, DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy, Epigenetics., 6, 20, 10.4161/epi.6.1.13362 Palmer, 2012, Insights into the genetic architecture of diabetic nephropathy, Curr Diab Rep., 12, 423, 10.1007/s11892-012-0279-2 Diamond-Stanic, 2012, Sugar, sex, and TGF-b in diabetic nephropathy, Semin Nephrol., 32, 261, 10.1016/j.semnephrol.2012.04.005 Campbell, 2011, Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes, Curr Diabetes Rev., 7, 3, 10.2174/157339911794273973 Rask-Madsen, 2013, Vascular complications of diabetes: mechanisms of injury and protective factors, Cell Metab., 17, 20, 10.1016/j.cmet.2012.11.012 Kanesaki, 2005, Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy, Am J Kidney Dis., 45, 288, 10.1053/j.ajkd.2004.09.020 Ruggenenti, 1998, The nephropathy of non-insulin-dependent diabetes: predictors of outcome relative to diverse patterns of renal injury, J Am Soc Nephrol., 9, 2336, 10.1681/ASN.V9122336 Ekinci, 2013, Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function, Diabetes Care., 36, 3620, 10.2337/dc12-2572 Haraldsson, 2008, Properties of the glomerular barrier and mechanisms of proteinuria, Physiol. Rev., 88, 451, 10.1152/physrev.00055.2006 Mogensen, 1984, Predicting diabetic nephropathy in insulin-dependent patients, N Engl J Med., 311, 89, 10.1056/NEJM198407123110204 Alvarez-Arroyo, 2003, Role of VEGF in the cellular response to injury, Nefrologia., 23, 54 De Boer IH; DCCT/EDIC Research Group. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:24-30. Bangstad, 1994, Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy, Diabetologia., 37, 483, 10.1007/s001250050136 Fioretto, 1993, Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys, Lancet., 342, 1193, 10.1016/0140-6736(93)92183-T Haraguchi, 2009, Complete remission of diabetic nephropathy in a type 1 diabetic patient with near-nephrotic range proteinuria and reduced renal function, Diabetes Res Clin Pract., 83, 295, 10.1016/j.diabres.2008.10.019 Iaconelli, 2011, Effects of bilio-pancreatic diversion on diabetic complications: a 10-year follow-up, Diabetes Care., 34, 561, 10.2337/dc10-1761 Veron, 2010, Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease, Kidney Int., 77, 989, 10.1038/ki.2010.64 Veron, 2011, Podocyte vascular endothelial growth factor (Vegf164) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes, Diabetologia., 54, 1227, 10.1007/s00125-010-2034-z Veron, 2014, Podocyte-specific VEGF-A gain of function induces nodular glomerulosclerosis in eNOS null mice, J Am Soc Nephrol., 25, 1814, 10.1681/ASN.2013070752 Dessapt-Baradez, 2014, Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease, J Am Soc Nephrol., 25, 33, 10.1681/ASN.2012121218 Hohenstein Bl, 2006, Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man, Kidney Int., 69, 1654, 10.1038/sj.ki.5000294 Patari, 2003, Nephrinuria in diabetic nephropathy of type 1 diabetes, Diabetes., 52, 2969, 10.2337/diabetes.52.12.2969 Hoshi, 2002, High glucose induced VEGF expression via PKC and ERK in glomerular podocytes, Biochem Biophys Res Commun., 290, 177, 10.1006/bbrc.2001.6138 Wen, 2013, Resveratrol attenuates diabetic nephropathy via modulating angiogenesis, PLoS One., 8, e82336, 10.1371/journal.pone.0082336 Warren, 2014, A Ligand-Independent VEGFR2 signaling pathway limits angiogenic responses in diabetes, Sci Signal., 7, ra1, 10.1126/scisignal.2004235 Sivaskandarajah, 2012, Vegfa protects the glomerular microvasculature in diabetes, Diabetes., 61, 2958, 10.2337/DB11-1655 Veron, 2011, Acute podocyte VEGF-A knockdown disrupts Alphav Beta3 integrin signaling in the glomerulus, J Am Soc Nephrol., 22, 29A Schrijvers, 2006, A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat, Nephrol Dial Transplant., 21, 324, 10.1093/ndt/gfi217 Hale, 2013, Insulin directly stimulates VEGF-A production in the glomerular podocyte, Am J Physiol Renal Physiol., 305, 182, 10.1152/ajprenal.00548.2012 Coward, 2007, Nephrin is critical for the action of insulin on human glomerular podocytes, Diabetes., 56, 1127, 10.2337/db06-0693 De Cosmo, 2013, Role of insulin resistance in kidney dysfunction: insights into the mechanism and epidemiological evidence, Nephrol Dial Transplant., 28, 29, 10.1093/ndt/gfs290 Kobayashi, 2005, Insulin resistance in patients with chronic kidney disease, Am J Kidney Dis., 45, 275, 10.1053/j.ajkd.2004.09.034 Mima, 2012, Glomerular VEGF resistance induced by PKCδ/SHP-1 activation and contribution to diabetic nephropathy, FASEB J., 26, 2963, 10.1096/fj.11-202994 Nakagawa, 2007, Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy, J Am Soc Nephrol., 18, 539, 10.1681/ASN.2006050459